Patents by Inventor Georg Watzig

Georg Watzig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NICOTINAMIDE, NICOTINAMIDE PRECURSORS AND NICOTINAMIDE METABOLITES AND COMPOSITIONS THEREOF FOR REDUCING THE TIME TO RESOLUTION OF SYMPTOMS IN PATIENTS WITH COVID-19 AND OTHER VIRAL INFECTIONS
    Publication number: 20230414599
    Abstract: The present invention relates to nicotinamide (niacinamide) or suitable precursors or metabolites thereof and compositions thereof for use for reducing the time to resolution of one or more symptoms in patients with COVID-19 or in patients with other viral infections.
    Type: Application
    Filed: November 26, 2021
    Publication date: December 28, 2023
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg WÄTZIG, Stefan SCHREIBER
  • PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
    Publication number: 20230235020
    Abstract: The invention provides a polypeptide dimer comprising two gp130-Fc fusion peptides for use in the treatment of ASCVD in human patients, preferably of high-risk ASCVD in human patients, more preferably of very-high-risk ASCVD in human patients.
    Type: Application
    Filed: June 9, 2021
    Publication date: July 27, 2023
    Inventors: Dominik Schulte, Georg Wätzig, Matthias Laudes, Stefan Schreiber
  • SHELLAC MICROCAPSULE FORMULATIONS AND COMPOSITIONS FOR TOPICAL INTESTINAL DELIVERY OF VITAMIN B3
    Publication number: 20210275513
    Abstract: The present invention relates to microcapsules comprising a core containing vitamin B3, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.
    Type: Application
    Filed: April 12, 2017
    Publication date: September 9, 2021
    Applicants: CONARIS RESEARCH INSTITUTE AG, CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL
    Inventors: Karin SCHWARZ, Julia KEPPLER, Eva-Maria THEISMANN, Jörg KNIPP, Daniela FANGMANN, Matthias LAUDES, Stefan SCHREIBER, Georg WÄTZIG
  • Pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
    Patent number: 10888555
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 12, 2021
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Wätzig, Dirk Seegert
  • Pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
    Patent number: 10758552
    Abstract: The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: September 1, 2020
    Assignee: CONARIS RESEARCH INSTITUTE AG
    Inventors: Georg Wätzig, Dirk Seegert
  • SHELLAC MICROCAPSULE FORMULATIONS AND COMPOSITIONS
    Publication number: 20190105278
    Abstract: The present invention relates to microcapsules comprising a core containing an active substance, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.
    Type: Application
    Filed: April 12, 2017
    Publication date: April 11, 2019
    Applicants: CONARIS RESEARCH INSTITUTE AG, CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL
    Inventors: Georg WÄTZIG, Karin SCHWARZ, Julia KEPPLER, Eva-Maria THEISMANN, Jörg KNIPP, Mark ELLROCHMANN, Stefan SCHREIBER
  • PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE FOR BENEFICALLY INFLUENCING BLOOD LIPID LEVELS BY MODIFYING THE INTESTINAL MICROBIOTA
    Publication number: 20170027924
    Abstract: The present invention relates to a new pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or related compounds for beneficially influencing the intestinal microbiota and blood lipid levels. In certain embodiments, the pharmaceutical composition is partially or entirely released into the lower small intestine and/or large intestine.
    Type: Application
    Filed: December 12, 2014
    Publication date: February 2, 2017
    Applicant: Conaris Research Institute AG
    Inventors: Georg Wätzig, Dirk Seegert
  • A PHARMACEUTICAL COMPOSITION CONTAINING COMBINATIONS OF NICOTINAMIDE AND 5-AMINOSALICYLIC ACID FOR BENEFICIALLY INFLUENCING THE INTESTINAL MICROBIOTA AND/OR TREATING GASTROINTESTINAL INFLAMMATION
    Publication number: 20160317557
    Abstract: The present invention relates to a new pharmaceutical composition containing a combination of 5-aminosalicylic acid and nicotinamide or related compounds. The combination is believed to beneficially influence the intestinal microbiota and/or reduce gastrointestinal inflammation. In certain embodiments, the pharmaceutical composition is partially or entirely released into the small intestine or large intestine.
    Type: Application
    Filed: December 12, 2014
    Publication date: November 3, 2016
    Applicant: CONAIRS RESEARCH INSTITUTE AG
    Inventors: Georg Watzig, Dirk Seegert
  • Optimized nucleotide sequences encoding sgp130
    Patent number: 8206948
    Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: June 26, 2012
    Assignee: Conaris Research Institute AG
    Inventors: Dirk Seegert, Georg Wätzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
  • Optimized Nucleotide Sequences Encoding Sgp 130
    Publication number: 20080199906
    Abstract: Described are codon optimized sgp130 encoding nucleic acid molecules as well as a method for the highly efficient recombinant production of sgp130 in mammalian cells or bacteria using a nucleic acid molecule of the invention.
    Type: Application
    Filed: August 26, 2005
    Publication date: August 21, 2008
    Applicant: CONARIS RESEARCH INSTITUTE AG
    Inventors: Dirk Seegert, Georg Watzig, Nikolaus Rahaus, Jessica Daecke, Stefan Rose-John
  • Pegylated Soluble Gp130-Dimers Useful as a Medicament
    Publication number: 20070270334
    Abstract: A polypeptide-dimer comprising two soluble gp130 molecules is described, wherein at least one of said soluble gp130 molecules is covalently linked to polyethylene glycol. Furthermore, a pharmaceutical composition containing said dimer and various medical uses are described.
    Type: Application
    Filed: June 23, 2004
    Publication date: November 22, 2007
    Inventors: Dirk Seegert, Stefan Schreiber, Stefan Rose-John, Georg Watzig, Nikolaus Rahaus